PEG-Intron peginterferon alfa-2b: Phase III data; under FDA review and marketed in Europe

ENZN and partner Schering-Plough Corp. (SGP, Kenilworth, N.J.) said data from a 48-week international Phase III

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE